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Abstract
Botulinum neurotoxin has achieved substantial clinical benefits in neurogenic detrusor overactivity.
More contentious has been its extension to management of refractory idiopathic detrusor over-
activity, in which risk of impaired voiding function and consequent need for intermittent
catheterisation may counteract the quality-of-life benefits of improved storage function. Several
issues remain uncertain for this unlicensed treatment, and clear insights into long-term consequences
are needed before it can be regarded as an established mainstream treatment.
Introduction and context
In the context of lower urinary tract (LUT) dysfunction,
botulinum neurotoxin-A (BoNT-A) was first used to treat
neurogenic bladder caused by spinal cord injury. The
substantial improvement in symptom severity achieved
represented a clear advance in clinical management
options, and benefits in other neurological conditions
such as multiple sclerosis were subsequently documen-
ted. The benefits relate to improved LUT storage function
as exemplified by reduced amplitude of detrusor over-
activity (DO) and incontinence severity. In neurogenic
LUT dysfunction, intravesical BoNT-A treatment carries a
significant likelihood of further impairing voiding
efficiency, ranging from voiding symptoms through
raised post-void residual to inability to pass urine.
Accordingly, the majority of patients with neurogenic
LUT dysfunction require intermittent catheterisation
(IC). IC is commonly employed as a management
option in this patient group as a consequence of voiding
dysfunction resulting from the neurological disease and
is generally well tolerated (perhaps because of neuro-
genic sensory impairment affecting the urethra). Thus,
additional impairment of voiding efficiency resulting
from intravesical BoNT-A treatment has not generally
been regarded as a contraindication to its use. Clinical
uptake of the method has been widespread, with two key
issues outstanding: (a) the need for regulatory approval,
as the technique is currently unlicensed, and (b) the need
for long-term studies demonstrating that improved LUT
storage parameters translate into preservation of upper
urinary tract function.
The success of intravesical BoNT-A treatment in the
neurogenic context has led to extrapolation to idiopathic
DO. This is more contentious for several reasons, for
example;
1. Indications for intervention. There is no compelling
medical reason to intervene since preservation of upper
urinary tract function is rarely a consideration. Thus,
treatment is primarily aimed at improving quality of life,
yet exchanging storage failure for voiding failure is not
necessarily regarded as an improvement by the indivi-
dual involved. Most studies have undertaken urody-
namic tests to evaluate filling and voiding function
before injection, and most published research has been
based on patients with idiopathic DO. Where patients
have idiopathic overactive bladder (OAB) symptoms (as
defined by symptomatic complaint of urinary urgency)
but do not have DO when assessed via urodynamics, less
information is available. Although benefits have been
reported [1], the use of BoNT-A in this group requires
particular care. Key markers for predicting response to
treatment have not been identified thus far [2], except
that a high maximum detrusor pressure may predict poor
treatment outcome [3].
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widespread use in this group of patients, and the
potential emergence of voiding dysfunction as a con-
sequence of treatment effectively leaves the patient faced
with a choice between having to tolerate refractory
storage failure or replacing it with de novo voiding failure.
Risk of needing IC postoperatively varies widely
(reviewed in [4]). It is thus prudent to inform patients
fully about the potential consequences of proceeding
and to train them in IC prior to injection since some
patients find themselves unable to carry out the
procedure. The ability to predict which patients are
most at risk of developing voiding dysfunction would be
advantageous. Urodynamically, projected isovolumetric
pressure in women and bladder contractility index in
men may be relevant [5], but further information is
needed.
3. Risk of systemic adverse effects.The number of side effects
that have been reported is low, but the need for safety
measures is emphasized. In April 2009, the American
regulatory authorities issued guidance on the risks of
serious adverse events associated with systemic spread of
the toxin [6]. They emphasized that physicians need to
warn patients about the potential for effects following
administration of botulinum toxins such as unexpected
loss of strength or muscle weakness, hoarseness or
trouble talking, trouble saying words clearly, loss of
bladder control, trouble breathing, trouble swallowing,
double vision, blurred vision, and drooping eyelids.
These have been reported as early as several hours and as
late as several weeks after treatment, and patients need to
be advised to seek immediate medical attention if they
develop any of these symptoms. Health care profes-
sionals and consumers can report serious adverse events
through the US Food and Drug Adminstration’s
MedWatch Adverse Event Reporting Program.
4. Regimes of administration. Approaches to administering
treatment are not currently standardised. Dose, depth of
injection (into the detrusor or suburothelial), bladder
region (whether or not the trigone is injected and even
the prostate gland in men [7]), anaesthesia, and BoNT-A
brand (BoTox or Dysport) are each sources of variation
which might influence the interpretation of outcomes.
Results of large-scale licensing trials which may even-
tually inform a more standardised approach (depending
on outcome) are awaited. More information is needed
before this realistically can be anticipated [8].
5. Duration of initial response and response to repeat
treatment. Efficacy is not as well sustained in idiopathic
DO as in neurogenic DO; duration of improved
symptom severity varies between studies, but 6 months
is a suitable ballpark figure to quote to patients.
A substantial proportion of patients see a return of
symptom control when injections are repeated, but not
all do so. Accordingly, it is not appropriate to expect
lifelong symptom control in this group of patients until
long-term follow-up studies have been completed. This
information is a long way off and needs to identify key
parameters, such as subgroups standing the best chance
of sustained response, whether risk of voiding dysfunc-
tion increases, whether functional behaviour of the
urinary tract deteriorates (e.g., filling compliance of the
bladder) and whether quality-of-life improvement is
sustained. Even in neurogenic DO, which is regarded as
having a better initial response and a good prospect with
repeat injection, the longer-term response is down to
74% at the fourth administration and, worryingly, with
some suggestion that detrusor contractility does not
recover fully [9].
6. Health economics. Treatment purchasers tend to regard
funding of treatments aimed at quality-of-life improve-
ment as a lower priority. Studies demonstrating cost-
effectiveness and cost utility will be needed to establish
intravesical BoNT-A treatment in health service provi-
sion. The treatment is expensive in relation to drug
purchase, treatment delivery, repeated treatment and
proportionate need for provision of catheters for IC.
While savings can be anticipated from the reduced use of
incontinence containment products and antimuscarinic
pharmaceuticals, real benefits for quality of life and
social/employment function will be essential before
health economics favour supporting provision of the
treatment method.
The pressing need for larger placebo-controlled and
comparative trials to evaluate the efficacy of single and
repeat injections, the duration of effect, the optimal
dosage and injection technique, the timing for repeat
injection, and the short- and long-term safety of the
treatment in LUT and pelvic floor disorders is clearly
emphasized by the medical profession [10].
Recent advances
1. Some work is suggesting that lower doses of BoNT-A
can be effective for symptom control (for example, [11])
in idiopathic DO. This is still not established, nor is
longevity of response or whether repeated injections
achieve equivalent symptom improvement.
2. The mechanisms of action involved may be more
diverse than impairment of acetylcholine release from
motor nerves. Sensory parameters (e.g., urgency severity)
appear to be affected rapidly [12], and altered neuropep-
tide release has been reported in animal models [13].
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OAB pathophysiology and response to BoNT-A.
3. In neurogenic DO, symptom benefits and improve-
ment in urodynamic parameters have been reported in a
more diverse group of patients, including those with
Parkinson’s disease [14] and multiple sclerosis [15].
4. Use in situations outside DO and OAB, including
bladder neck dyssynergia [16], urogenital pain syn-
dromes (e.g., [17]) and acute urinary retention in men
[18], has been attempted. Nonetheless, these small-scale
studies should be regarded as providing interesting
priming data for future research rather than serving as a
basis for clinical management.
5. Altering the molecular structure and related proteins of
the administered agent may represent a strategy to
modulate the balance of efficacy and unwanted effects,
potentially strengthening the case for long-term clinical
treatment. Animal studies of at least one such formula-
tion have been undertaken [19]. Additionally, combin-
ing BoNT-A with intravesical instillation of dimethyl
sulphoxide to administer the agent without the need for
injection has been reported [20].
Implications for clinical practice
Intravesical BoNT-A treatment is becoming widely
accepted in the medical community for the treatment
of symptoms caused by neurogenic DO. It remains
unlicensed as yet, but the clinical trials required for
regulatory approval are in progress. Certainly, many
patients experience better storage function when intra-
vesical BoNT-A treatment is combined with IC, and this
has been recognised (e.g., the UK statement on bladder
management in multiple sclerosis [21]). Key issues in
this context include the potential contribution of the
treatment in maintaining a ‘safe bladder’ [i.e., one that
will not endanger upper urinary tract function due to
reduced filling compliance, DO in the presence of vesico-
ureteric reflux, or detrusor sphincter dyssynergia (DSD)].
It is crucial that BoNT-A treatment sustain the improved
life expectancy in neurogenic bladder achieved through
better protection of renal function over the last decades.
Clinicians are also using BoNT-A for additional benefits,
such as sphincter injections in DSD and reduction of
bladder spasms in patients with indwelling urinary
catheters.
Idiopathic DO is less clear-cut, and clinicians need to
consider carefully whether they are exposing patients to
potential problems. In the immediate aftermath, the
majority of patients manage to void adequately, but the
difficulty predicting who will need IC means the patient
must fully understand the risk and precisely what IC
entails. Short-term response rates in idiopathic DO are
lower than in neurogenic DO and quality-of-life
improvement is also less clear-cut. In the medium
term, there is some suspicion that detrusor contractility
may be impaired, potentially leading to increased
numbers of patients needing IC. The longer term entails
even greater uncertainty; is it really realistic to anticipate
lifelong treatment at 6-month intervals? What is the
attrition rate of treatment response? What will be the
severity of the symptoms: improved as the bladder is
trained to cope with greater volumes or increased as
neural plasticity alters the pathophysiology of the
condition?
Besides the interest for BoNT-A, other treatments for
refractory DO such as sacral nerve stimulation are less
used and seem to be less known by the urological
community and general practitioners. However, this
treatment has received a grade A recommendation for
refractory DO from the fourth International Consulta-
tion on Incontinence. Patients should be informed not
only about the different options for their refractory OAB
symptoms but also about the level of evidence for these
treatments in order to enable them to make a properly
informed decision.
Conclusions
Intravesical BoNT-A treatment can achieve many bene-
fits, but refinement of the protocols and clarification of
long-term effects are essential in both neurogenic and
idiopathic DO. Use of the treatment is acceptable only
where patients are fully counselled as to uncertainty and
risk and where clinicians maintain close surveillance of
their treated patients and keep aware of scientific
developments. Further research is needed clinically, but
at the basic science level, research into the mechanisms
underlying clinical response may yield information on
potential targets for the development of new treatment
approaches.
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